Released Nov 16, 2026, before the open
10-Q filed Nov 16, 2026, 47 days after period end · 0001193125-26-462097
On November 16, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 |
|---|---|---|---|
| Net Income | -$51.62M | -$29.42M | -$19.02M |
| EPS Diluted | -$0.97 | -$37.18 | -$25.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MapLight Therapeutics, Inc. · CIK 1770069 · Engraved from SEC EDGAR
ended Sep 30, 2026 · filed Nov 16, 2026 · 47 d after period end
MapLight Therapeutics reported a net loss of $51.6 million for the third quarter of 2026, compared with $29.4 million for the third quarter of 2025.¶2
Research and development expenses were $44.2 million and general and administrative expenses were $11.1 million for the third quarter of 2026.¶3¶4
Cash, cash equivalents and investments were $463.4 million as of September 30, 2026, and the company expects them to fund advancement of ML-007C-MA through 2028.¶5
The company completed a $150 million private placement in August 2026 and is pausing significant further investment in preclinical and discovery-stage programs.¶6¶7